Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsTherapeutic antibody development is often hindered by inconsistent effector function, patient-specific efficacy variability, and rigorous quality control requirements for glycosylation. Creative Biolabs' Functional Glycoform Screening & Correlation Service bridges these gaps via a unified analytical strategy. By linking detailed glycan profiles to biological activity and receptor engagement, we support the definition and refinement of vital quality attributes. This facilitates immunogenicity mitigation, therapeutic enhancement, and streamlined regulatory submissions through actionable insights.
Glycosylation profoundly influences the safety and efficacy of therapeutic monoclonal antibodies by regulating effector functions, pharmacokinetics, and immunogenicity. However, conventional analytical approaches often lack the sensitivity and resolution to fully characterize clinically relevant glycan microheterogeneity. Our service overcomes these limitations through a cutting-edge analytical platform, delivering ultra-sensitive and high-resolution glycoform profiling with detection limits as low as 5 attomoles and a dynamic range spanning over six orders of magnitude.
Fig.1 Functional glycoform profiling and linkage analysis.
Our Antibody Glycosylation Analysis & Characterization Services deliver a comprehensive, one-stop solution for in-depth profiling of antibody glycosylation. A key highlight of this platform is our specialized Functional Glycoform Screening & Correlation Service. Creative Biolabs delivers a comprehensive roadmap that transforms raw glycan data into actionable therapeutic insights. We don't just provide a list of sugar structures; we provide the functional correlation. By identifying the exact "master regulator" glycans within your mAb or vaccine candidate, we enable you to select the most potent lead candidates and optimize your bioprocessing parameters for maximum clinical impact.
Our service provides comprehensive, data-driven correlations between specific glycoforms and critical therapeutic attributes. This enables the rational optimization of antibody efficacy, safety, and pharmacokinetics throughout development.
Required Starting Materials: To commence the service, a purified sample of monoclonal antibody (mAb), recombinant protein, or viral immunogen is required, with a recommended quantity of 1-2 mg. Submission of essential sequence details and any available prior binding data is also requested to establish a reference for evaluating initial sample performance.
Key Steps:
Final Deliverables: Upon service completion, a Glyco-Functional Correlation Report will be provided, featuring deconvoluted spectra, allotype-specific affinity rankings, and strategic guidance for subsequent lead optimization.
Our platform bridges advanced structural analysis with practical biomanufacturing insights. We specialize in detecting rare, immunogenic glycans down to 5 amol, a sensitivity rigorously validated and reproducible. Beyond identification, we provide actionable data to optimize candidate binding, including rescue strategies for weak-binding allotypes, turning potential failures into viable therapies for diverse patient populations.
"Creative Biolabs' platform enabled the identification of rare high-mannose variants in our oncology mAbs at a 5 amol detection limit—undetectable by our in-house HPLC methods. This capability was instrumental in de-risking immunogenicity ahead of IND submission." Dr. Julian S***.
"The detailed correlation of glycan structure with V158/F158 allotype binding transformed our candidate selection process. Their analysis guided a targeted galactosylation strategy, resulting in a lead candidate with triple the binding affinity for the F158 patient group." Dr. Elena M***.
"Chemoenzymatic Remodeling by Creative Biolabs delivered 100% homogeneous afucosylated IgG, resolving the glycan heterogeneity typical of production. The resulting high-definition data directly addressed specific requests from regulatory agencies." Prof. David K***.
For expert consultation on glycoform screening tailored to your cell-based therapy, contact our specialists. Let's translate complex glycan data into actionable development strategies. Reach out today to discuss your project and request a detailed proposal.
Contact Us for a Custom Consultation & Proposal.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
